Immunology of gynecologic neoplasms: Analysis of the prognostic significance of the immune status

Current Cancer Drug Targets

Volumn 9, Issue 4, 2009, Pages 541-565

  Bellati, F ^a   Visconti, V ^a   Napoletano, C ^a   Antonilli, M ^a   Frati, L ^a   Panici, P Benedetti ^a   Nuti, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Gynecological cancer; Immune response; Immune signatures; Prognostic indicators; TAA

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKINE; ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOGY 2 PROTEIN; GROWTH FACTOR; HLA ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; MELANOMA ANTIGEN 1; MUCIN 1; NY ESO 1 ANTIGEN; PLATINUM DERIVATIVE; PROTEIN P53; TAXANE DERIVATIVE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS PROTEIN; WART VIRUS VACCINE;

BRACHYTHERAPY; CANCER IMMUNOLOGY; CANCER STAGING; CANCER SURGERY; CELL CYCLE REGULATION; CYTOREDUCTION; DNA REPAIR; ENDOMETRIUM CANCER; ENZYME LINKED IMMUNOSPOT ASSAY; GYNECOLOGIC CANCER; HUMAN; HUMORAL IMMUNITY; IMMUNE STATUS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; OVARY CANCER; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS REPLICATION; VULVA CANCER; VULVECTOMY;

ANTIBODY FORMATION; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CYTOKINES; DRUG DELIVERY SYSTEMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PROGNOSIS; VIRAL PROTEINS;

EID: 67649402262     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909788486722     Document Type: Review

References (347)

1. van Vliet, S. J.; den Dunnen, J.; Gringhuis, S. I.; Geijtenbeek, T. B.; van Kooyk, Y. Innate signaling and regulation of Dendritic cell immunity. Curr. Opin. Immunol. 2007, 19, 435-440. (Pubitemid 47284852)
2. Lin, W. W.; Karin, M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117, 1175-1183. (Pubitemid 46718402)
3. Melief, C. J. Cancer: immune pact with the enemy. Nature 2007, 450, 803-804.
4. Prendergast, G. C.; Jaffee, E. M. Cancer immunologists and cancer biologists: why we didn't talk then but need to now. Cancer Res. 2007, 67, 3500-3504. (Pubitemid 46762127)
5. Zitvogel, L.; Tesniere, A.; Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 2006, 6, 715-727. (Pubitemid 44453458)
6. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification ofthe HER-2/neu oncogene. Science 1987, 235, 177-182. (Pubitemid 17231334)
7. Coussens, L.; Yang-Feng, T. L.; Liao, Y. C.; Chen, E.; Gray, A.; McGrath, J.; Seeburg, P. H.; Libermann, T. A.; Schlessinger, J.; Franche, U.; Levinson, A.; Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985, 230, 1132-1139. (Pubitemid 16169997)
8. Salomon, D. S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19, 183-232.
9. Lane, D. P.; Crawford, L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979, 278, 261-263. (Pubitemid 9129076)
10. Jenkins, J. R.; Rudge, K.; Currie, G. A. Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 1984, 312, 651-654. (Pubitemid 15218338)
11. Vousden, K. H.; Lane, D. P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007, 8, 275-283. (Pubitemid 46474662)
12. Sawan, A.; Randall, B.; Angus, B.; Wright, C.; Henry, J. A.; Ostrowski, J.; Hennessy, C.; Lennard, T. W.; Corbett, I.; Horne, C. H. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J. Pathol. 1992, 168, 23-28.
13. Yamaguchi, A.; Kurosaka, Y.; Fushida, S.; Kanno, M.; Yonemura, Y.; Miwa, K.; Miyazaki, I. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992, 70, 2778-2784.
14. Hattrup, C. L.; Gendler, S. J. Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol. 2008, 70, 431-457. (Pubitemid 351738187)
15. Gendler, S. J.; Lancaster, C. A.; Taylor-Papadimitriou, J.; Duhig, T.; Peat, N.; Burchell, J.; Pemberton, L.; Lalani, E. N.; Wilson, D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 1990, 265, 15286-15293. (Pubitemid 20296236)
16. Hollingsworth, M. A.; Swanson, B. J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 2004, 4, 45-60. (Pubitemid 38082153)
17. Hughes, O. D. M.; Denley, H.; Kunkler, R. B.; Denton, G.; Prince, M. R.; Perkins, A. C. MUC1 mucin expression in transitional cell carcinoma of the bladder. J. Urol. Pathol. 2000, 12, 179-191.
18. Bast, R. C. Jr.; Feeney, M.; Lazarus, H.; Nadler, L. M.; Colvin, R. B.; Knapp, R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 1981, 68, 1331-1337. (Pubitemid 12235035)
19. Bast, R. C. Jr.; Xu, F. J.; Yu, Y. H.; Barnhill, S.; Zhang, Z.; Mills, G. B. CA 125: the past and the future. Int. J. Biol. Markers 1998, 13, 179-187. (Pubitemid 29178546)
20. Bast, R. C. Jr.; Klug, T. L.; St John, E.; Jenison, E.; Niloff, J. M.; Lazarus, H.; Berkowitz, R. S.; Leavitt, T.; Griffiths, C. T.; Parker, L.; Zurawski, V. R. Jr.; Knapp, R. C. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 1983, 309, 883-887.
21. Grover, S.; Koh, H.; Weideman, P.; Quinn, M. A. The effect of the menstrual cycle on serum CA 125 levels: a population study. Am. J. Obstet. Gynecol. 1992, 167, 1379-1381.
22. Lehtovirta, P.; Apter, D.; Stenman, U. H. Serum CA 125 levels during the menstrual cycle. Br. J. Obstet. Gynaecol. 1990, 97, 930-933. (Pubitemid 20340626)
23. Göcze, P. M.; Szabó, D. G.; Than, G. N.; Csaba, I. F.; Krommer, K. F. Occurrence of CA 125 and CA 19-9 tumor-associated antigens in sera of patients with gynecologic, trophoblastic, and colorectal tumors. Gynecol. Obstet. Invest. 1988, 25, 268-272. (Pubitemid 18146916)
24. Jacobs, I.; Bast, R. C. Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum. Reprod. 1989, 4, 1-12. (Pubitemid 19069900)
25. Gold, P.; Freedman, S. O. Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med. 1965, 122, 467-481.
26. Gold, P.; Goldenberg, N. The carcinoembryonic antigen (CEA): past, present and future. McGill J. Med. 1997, 3, 46-66. (Pubitemid 27517709)
27. Berinstein, N. L. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J. Clin. Oncol. 2002, 20, 2197-2207. (Pubitemid 34408812)
28. Sahin, U.; Türeci, O.; Schmitt, H.; Cochlovius, B.; Johannes, T.; Schmits, R.; Stenner, F.; Luo, G.; Schobert, I.; Pfreundschuh, M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 1995, 92, 11810-11813. (Pubitemid 26014201)
29. Türeci, O.; Sahin, U.; Zwick, C.; Koslowski, M.; Seitz, G.; Pfreundschuh, M. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc. Natl. Acad. Sci. USA 1998, 95, 5211-5216. (Pubitemid 28208577)
30. Chomez, P.; De Backer, O.; Bertrand, M.; De Plaen, E.; Boon, T.; Lucas, S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001, 61, 5544-5551. (Pubitemid 32694940)
31. Park, J. H.; Kong, G. H.; Lee, S. W. hMAGE-A1 overexpression reduces TNF-alpha cytotoxicity in ME-180 cells. Mol. Cells. 2002, 14, 122-129. (Pubitemid 41582989)
32. Glynn, S. A.; Gammell, P.; Heenan, M.; O'Connor, R.; Liang, Y.; Keenan, J.; Clynes, M. A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin. Br. J. Cancer 2004, 91, 1800-1807. (Pubitemid 39664968)
33. Sienel, W.; Mecklenburg, I.; Dango, S.; Ehrhardt, P.; Kirschbaum, A.; Passlick, B.; Pantel, K. Detection of MAGE-A transcripts in bone marrow is an independent prognostic factor in operable non-small-cell lung cancer. Clin. Cancer Res. 2007, 13, 3840-3847. (Pubitemid 47037589)
34. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M. J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71-96.
35. Berek, J. S.; Bertelsen, K.; du Bois, A.; Brady, M. F.; Carmichael, J.; Eisenhauer, E. A.; Gore, M.; Grenman, S.; Hamilton, T. C.; Hansen, S. W.; Harper, P. G.; Horvath, G.; Kaye, S. B.; Lück, H. J.; Lund, B.; McGuire, W. P.; Neijt, J. P.; Ozols, R. F.; Parmar, M. K.; Piccart-Gebhart, M. J.; van Rijswijk, R.; Rosenberg, P.; Rustin, G. J.; Sessa, C.; Thigpen, J. T.; Tropè, C.; Tuxen, M. K.; Vergote, I.; Vermorken, J. B.; Willemse, P. H.; Advanced epithelial ovarian cancer: 1998 consensus statements. Ann. Oncol. 1999, 10(Suppl 1), 87-92.
36. Bristow, R. E.; Tomacruz, R. S.; Armstrong, D. K.; Trimble, E. L.; Montz, F. J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis. J. Clin. Oncol. 2002, 20, 1248-1259. (Pubitemid 34177431)
37. Ozols, R. F.; Bundy, B. N.; Greer, B. E.; Fowler, J. M.; Clarke- Pearson, D.; Burger, R. A.; Mannel, S.; DeGeest, K.; Hartenbach, E. M.; Baergen, R. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 2003, 21, 3194-3200. (Pubitemid 46606249)
38. Heintz, A. P.; Odicino, F.; Maisonneuve, P.; Quinn, M. A.; Benedet, J. L.; Creasman, W. T.; Ngan, H. Y.; Pecorelli, S.; Beller, U. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 2006, 95(Suppl 1), S161-S192.
39. Berchuck, A.; Kamel, A.; Whitaker, R.; Kerns, B.; Olt, G.; Kinney, R.; Soper, J. T.; Dodge, R.; Clarke-Pearson, D. L.; Marks, P., Mckenzie, S.; Yin, S.; Bast, R. C. Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990, 50, 4087-4091. (Pubitemid 20225635)
40. Natali, P. G.; Nicotra, M. R.; Bigotti, A.; Venturo, I.; Slamon, D. J.; Fendly, B. M.; Ullrich, A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int. J. Cancer 1990, 45, 457-461. (Pubitemid 20087192)
41. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich, A.; Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712. (Pubitemid 19147683)
42. Zhang, X.; Silva, E.; Gershenson, D.; Hung, M. C. Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. Oncogene 1989, 4, 985-989. (Pubitemid 19202814)
43. Wang, Y.; Kristensen, G. B.; Helland, A.; Nesland, J. M.; Børresen- Dale, A. L.; Holm, R. Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am. J. Clin. Pathol. 2005, 124, 392-401. (Pubitemid 41232925)
44. Camilleri-Broët, S.; Hardy-Bessard, A. C.; Le Tourneau, A.; Paraiso, D.; Levrel, O.; Leduc, B.; Bain, S.; Orfeuvre, H.; Audouin, J.; Pujade-Lauraine, E. GINECO group. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann. Oncol. 2004, 15, 104-112. (Pubitemid 38145531)
45. Høgdall, E. V.; Christensen, L.; Kjaer, S. K.; Blaakaer, J.; Bock, J. E.; Glud, E.; Nørgaard-Pedersen, B.; Høgdall, C. K. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003, 98, 66-73. (Pubitemid 36741127)
46. Hartmann, L. C.; Podratz, K. C.; Keeney, G. L.; Kamel, N. A.; Edmonson, J. H.; Grill, J. P.; Su, J. Q.; Katzmann, J. A.; Roche, P. C. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J. Clin. Oncol. 1994, 12, 64-69. (Pubitemid 24020622)
47. Klemi, P. J.; Pylkkänen, L.; Kiilholma, P.; Kurvinen, K.; Joensuu, H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995, 76, 1201-1208.
48. Pieretti, M.; Hopenhayn-Rich, C.; Khattar, N. H.; Cao, Y.; Huang, B.; Tucker, T. C. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest. 2002, 20, 11-23. (Pubitemid 34151056)
49. Shahin, M. S.; Hughes, J. H.; Sood, A. K.; Buller, R. E. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000, 89, 2006-2017. (Pubitemid 30804755)
50. Skirnisdóttir, I.; Sorbe, B.; Seidal, T. P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. Int. J. Gynecol. Cancer 2001, 11, 147-158. (Pubitemid 32381664)
51. Tewari, K. S.; Kyshtoobayeva, A. S.; Mehta, R. S.; Yu, I. R.; Burger, R. A.; DiSaia, P. J.; Fruehauf, J. P. Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol. Oncol. 2000, 78, 130-136. (Pubitemid 30650342)
52. Hall, J.; Paul, J.; Brown, R. Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert. Rev. Mol. Med. 2004, 6, 1-20. (Pubitemid 43118253)
53. Geisler, J. P.; Geisler, H. E.; Wiemann, M. C.; Givens, S. S.; Zhou, Z.; Miller, G. A. Quantification of p53 in epithelial ovarian cancer. Gynecol. Oncol. 1997, 66, 435-438. (Pubitemid 27388136)
54. Levesque, M. A.; Katsaros, D.; Yu, H.; Zola, P.; Sismondi, P.; Giardina, G.; Diamandis, E. P. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995, 75, 1327-1338.
55. Röhlke, P.; Milde-Langosch, K.; Weyland, C.; Pichlmeier, U.; Jonat, W.; Löning, T. p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity. J. Cancer Res. Clin. Oncol. 1997, 123, 496-501. (Pubitemid 27436009)
56. Viale, G.; Maisonneuve, P.; Bonoldi, E.; Di Bacco, A.; Bevilacqua, P.; Panizzoni, G. A.; Radaelli, U.; Gasparini, G. The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients. Ann. Oncol. 1997, 8, 469-476. (Pubitemid 27310692)
57. Eltabbakh, G. H.; Belinson, J. L.; Kennedy, A. W.; Biscotti, C. V.; Casey, G.; Tubbs, R. R.; Blumenson, L. E. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 1997, 80, 892-898. (Pubitemid 27360471)
58. Hashiguchi, Y.; Tsuda, H.; Inoue, T.; Nishimura, S.; Suzuki, T.; Kawamura, N. Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum. Pathol. 2004, 35, 165-175. (Pubitemid 38240898)
59. Silvestrini, R.; Daidone, M. G.; Veneroni, S.; Benini, E.; Scarfone, G.; Zanaboni, F.; Villa, A.; Presti, M.; Danese, S.; Bolis, G. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer 1998, 82, 159-167. (Pubitemid 28070493)
60. Dogan, E.; Saygili, U.; Tuna, B.; Gol, M.; Gürel, D.; Acar, B.; Koyuncuoǧlu, M. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer:a multivariate analysis. Gynecol. Oncol. 2005, 97, 46-52. (Pubitemid 40403673)
61. Buttitta, F.; Marchetta, A.; Gadducci, A.; Pellegrini, S.; Moranti, M.; Carnicelli, V.; Cosio, S.; Gagetti, O.; Genazzani, A. R.; Bevilacqua, G. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br. J. Cancer 1997, 75, 230-235. (Pubitemid 27019567)
62. Righetti, S. C.; Della Torre, G.; Pilotti, S.; Ménard, S.; Ottone, F.; Colnaghi, M. I.; Pierotti, M. A.; Lavarino, C.; Cornarotti, M.; Oriana, S.; Böhm, S.; Bresciani, G. L.; Spatti, G.; Zunino, F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996, 56, 689-693. (Pubitemid 26055453)
63. Wang, L.; Ma, J.; Liu, F.; Yu, Q.; Chu, G.; Perkins, A. C.; Li, Y. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol. Oncol. 2007, 105, 695-702. (Pubitemid 46734194)
64. McGuckin, M. A.; Hurst, T. G.; Ward, B. G. Heterogeneity in production, secretion and glycosylation of MUC1 epithelial mucin by primary cultures of ovarian carcinoma. Int. J. Cancer 1995, 63, 412-418.
65. Moore, R. G.; McMeekin, D. S.; Brown, A. K.; Disilvestro, P.; Miller, M. C.; Allard, W. J.; Gajewski, W.; Kurman, R.; Bast, R. C. Jr.; Skates, S. J. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2009, 112(1), 40-46.
66. Casper, S.; van Nagell, J. R. Jr.; Powell, D. F.; Dubilier, L. D.; Donaldson, E. S.; Hanson, M. B.; Pavlik, E. J. Immunohistochemical localization of tumor markers in epithelial ovarian cancer. Am. J. Obstet. Gynecol. 1984, 149, 154-158. (Pubitemid 14103907)
67. Charpin, C.; Bhan, A. K.; Zurawski, V. R. Jr.; Scully, R. E. Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9)localization in 121 primary and metastatic ovarian tumors: an immunohistochemical study with the use of monoclonal antibodies. Int. J. Gynecol. Pathol. 1982, 1, 231-245.
68. Heald, J.; Buckley, C. H.; Fox, H. An immunohistochemical study of distribution of carcinoembryonic antigen in epithelial tumours of the ovary. J. Clin. Pathol. 1979, 32, 918-926. (Pubitemid 10249455)
69. Sato, E.; Olson, S. H.; Ahn, J.; Bundy, B.; Nishikawa, H.; Qian, F.; Jungbluth, A. A.; Frosina, D.; Gnjatic, S.; Ambrosone, C.; Kepner, J.; Odunsi, T.; Ritter, G.; Lele, S.; Chen, Y. T.; Ohtani, H.; Old, L. J.; Odunsi, K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 18538-18543. (Pubitemid 43011261)
70. Yakirevich, E.; Sabo, E.; Lavie, O.; Mazareb, S.; Spagnoli, G. C.; Resnick, M. B. Expression of the MAGE-A4 and NY-ESO-1 cancer- testis antigens in serous ovarian neoplasms. Clin. Cancer Res. 2003, 9, 6453-6460. (Pubitemid 38031833)
71. Diederichsen, A. C.; Hjelmborg, J. B.; Christensen, P. B.; Zeuthen, J.; Fenger, C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol. Immunother. 2003, 52, 423-428. (Pubitemid 36831363)
72. Halpern, A. C.; Schuchter, L. M. Prognostic models in melanoma. Semin. Oncol. 1997, 24(1 Suppl 4), S2-S7.
73. Marrogi, A. J.; Munsi, A.; Merogi, A. J.; Ohadike, Y.; El-Habashi, A.; Marrogi, O. L.; Freeman, S. M. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int. J. Cancer 1997, 74, 492-501. (Pubitemid 27486505)
74. Vesalainen, S.; Lipponen, P.; Talja, M.; Syrjänen, K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur. J. Cancer 1994, 30A, 1797-1803. (Pubitemid 24377155)
75. Zhang, L.; Conejo-Garcia, J. R.; Katsaros, D.; Gimotty, P. A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Schlienger, K.; Liebman, M. N.; Rubin, S. C.; Coukos, G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348, 203-213. (Pubitemid 36077915)
76. Raspollini, M. R.; Castiglione, F.; Rossi Degl'innocenti, D.; Amunni, G.; Villanucci, A.; Garbini, F.; Baroni, G.; Taddei, G. L. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann. Oncol. 2005, 16, 590-596.
77. Tomsová, M.; Melichar, B.; Sedláková, I.; Steiner, I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol. Oncol. 2008, 108, 415-420. (Pubitemid 351174290)
78. Greenwald, R. J.; Freeman, G. J.; Scarpe, A. H. The B7 family revisited. Annu. Rev. Immunol. 2005, 23, 515-548. (Pubitemid 40563179)
79. Hamanishi, J.; Mandai, M.; Iwasaki, M.; Okazaki, T.; Tanaka, Y.; Yamaguchi, K.; Higuchi, T.; Yagi, H.; Takakura, K.; Minato, N.; Honjo, T.; Fujii, S. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA 2007, 104, 3360-3365. (Pubitemid 46364164)
80. Wang, H. Y.; Wang, R. F. Regulatory T cells and cancer. Curr. Opin. Immunol. 2007, 19, 217-223. (Pubitemid 46356965)
81. Curiel, T. J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J. R.; Zhang, L.; Burow, M.; Zhu, Y.; Wei, S.; Kryczek, I.; Daniel, B.; Gordon, A.; Myers, L.; Lackner, A.; Disis, M. L.; Knutson, K. L.; Chen, L.; Zou, W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10, 942-949. (Pubitemid 39273735)
82. Viguier, M.; Lemaître, F.; Verola, O.; Cho, M. S.; Gorochov, G.; Dubertret, L.; Bachelez, H.; Kourilsky, P.; Ferradini, L. Foxp3 expressing CD4+CD25(high) regulatory T cells are over-represented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 2004, 173, 1444-1453. (Pubitemid 38924326)
83. Wolf, D.; Wolf, A. M.; Rumpold, H.; Fiegl, H.; Zeimet, A. G.; Muller-Holzner, E.; Deibl, M.; Gastl, G.; Gunsilius, E.; Marth, C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 2005, 11, 8326-8631. (Pubitemid 41746944)
84. Woo, E. Y.; Chu, C. S.; Goletz, T. J.; Schlienger, K.; Yeh, H.; Coukos, G.; Rubin, S. C.; Kaiser, L. R.; June, C. H. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001, 61, 4766-4772. (Pubitemid 32691889)
85. Mantovani, A.; Sozzani, S.; Locati, M.; Allavena, P.; Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23, 549-555. (Pubitemid 35223554)
86. Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4, 71-78. (Pubitemid 38082155)
87. Wyckoff, J.; Wang, W.; Lin, E. Y.; Wang, Y.; Pixley, F.; Stanley, E. R.; Graf, T.; Pollard, J. W.; Segall, J.; Condeelis, J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004, 64, 7022-7029. (Pubitemid 39331012)
88. Hiratsuka, S.; Nakamura, K.; Iwai, S.; Murakami, M.; Itoh, T.; Kijima, H.; Shipley, J. M.; Senior, R. M.; Shibuya, M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2002, 2, 289-300. (Pubitemid 41043963)
89. Lin, E. Y.; Nguyen, A. V.; Russell, R. G.; Pollard, J. W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001, 193, 727-740.
90. Duluc, D.; Delneste, Y.; Tan, F.; Moles, M. P.; Grimaud, L.; Lenoir, J.; Preisser, L.; Anegon, I.; Catala, L.; Ifrah, N.; Descamps, P.; Gamelin, E.; Gascan, H.; Hebbar, M.; Jeannin, P. Tumor associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007, 11, 4319-4330.
91. Hagemann, T.; Wilson, J.; Burke, F.; Kulbe, H.; Li, N. F.; Plüddemann, A.; Charles, K.; Gordon, S.; Balkwill, F. R. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J. Immunol. 2006, 176, 5023-5032.
92. Kryczek, I.; Zou, L.; Rodriguez, P.; Zhu, G.; Wei, S.; Mottram, P.; Brumlik, M.; Cheng, P.; Curiel, T.; Myers, L.; Lackner, A.; Alvarez, X.; Ochoa, A.; Chen, L.; Zou, W. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 2006, 203, 871-881.
93. Sica, G. L.; Choi, I. H.; Zhu, G.; Tamada, K.; Wang, S. D.; Tamura, H.; Chapoval, A. I.; Flies, D. B.; Bajorath, J.; Chen, L. B7- H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003, 18, 849-861. (Pubitemid 36776432)
94. Bethwaite, P. B.; Holloway, L. J.; Thornton, A.; Delahunt, B. Infiltration by immunocompetent cells in early stage invasive carcinoma of the uterine cervix: a prognostic study. Pathology 1996, 28, 321-327. (Pubitemid 27170919)
95. Wischatta, M.; Sprinzl, G. M.; Gunkel, A. R.; Hussl, B.; Romani, N.; Schrott-Fischer, A. Dendritic cells in selected head and neck tumors. Ann. Otol. Rhinol. Laryngol. 2000, 109, 56-62. (Pubitemid 30051782)
96. Zehntner, S.; Townsend, W.; Parkes, J.; Schmidt, C.; Down, M.; Bell, J.; Mulligan, R.; O'Rourke, M.; Ellem, K.; Thomas, R. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology 1999, 31, 116-122. (Pubitemid 29264056)
97. Eisenthal, A.; Polyvkin, N.; Bramante-Schreiber, L.; Misonznik, F.; Hassner, A.; Lifschitz-Mercer, B. Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Hum. Pathol. 2001, 32, 803-807. (Pubitemid 32803980)
98. Rudlowski, C.; Rath, W.; Becker, A. J.; Wiestler, O. D.; Buttner, R. Trastuzumab and breast cancer. N. Engl. J. Med. 2001, 345, 997-998.
99. Stevenson, G. T.; Stevenson, F. K. Treatment of lymphoid tumors with anti-idiotype antibodies. Springer Semin. Immunopathol. 1983, 6, 99-115.
100. Høgdall, E. V.; Høgdall, C. K.; Blaakaer, J.; Heegaard, N. H.; Glud, E.; Christensen, L.; Bock, J. E.; Nørgaard-Pedersen, B.; Wiik, A.; Kjaer, S. K. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis. APMIS 2002, 110, 545-553.
101. Abendstein, B.; Marth, C.; Müller-Holzner, E.; Widschwendter, M.; Daxenbichler, G.; Zeimet, A. G. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer 2000, 88, 1432-1437. (Pubitemid 30155182)
102. Angelopoulou, K.; Rosen, B.; Stratis, M.; Yu, H.; Solomou, M.; Diamandis, E. P. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer 1996, 78, 2146-2152. (Pubitemid 26367607)
103. Gadducci, A.; Ferdeghini, M.; Buttitta, F.; Cosio, S.; Fanucchi, A.; Annicchiarico, C.; Gagetti, O.; Bevilacqua, G.; Genazzani, A. R. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecol. Oncol. 1999, 72, 76-81. (Pubitemid 29045451)
104. Vogl, F. D.; Frey, M.; Kreienberg, R.; Runnebaum, I. B. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br. J. Cancer 2000, 83, 1338-1343. (Pubitemid 30839120)
105. Goodell, V.; Salazar, L. G.; Urban, N.; Drescher, C. W.; Gray, H.; Swensen, R. E.; McIntosh, M. W.; Disis, M. L. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J. Clin. Oncol. 2006, 24, 762-768. (Pubitemid 46622043)
106. Cramer, D. W.; Titus-Ernstoff, L.; McKolanis, J. R.; Welch, W. R.; Vitonis, A. F.; Berkowitz, R. S.; Finn, J. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 1125-1131. (Pubitemid 40656457)
107. Richards, E. R.; Devine, P. L.; Quin, R. J.; Fontenot, J. D.; Ward, B. G.; McGuckin, M. A. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol. Immunother. 1998, 46, 245-252. (Pubitemid 28332922)
108. Sugarman, B. J.; Aggarwal, B. B.; Hass, P. E.; Figari, I. S.; Palladino, M. A. Jr.; Shepard, H. M. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normaland transformed cells in vitro. Science 1985, 230, 943-945. (Pubitemid 16193990)
109. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315, 1650-1659. (Pubitemid 17052899)
110. Fràter-Schröder, M.; Risau, W.; Hallmann, R.; Gautschi, P.; Böhlen, P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc. Natl. Acad. Sci. USA 1987, 84, 5277-5281. (Pubitemid 17129009)
111. Ito, A.; Sato, T.; Iga, T.; Mori, Y. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS Lett. 1990, 269, 93-95. (Pubitemid 20245325)
112. Brenner, D. A.; O'Hara, M.; Angel, P.; Chojkier, M.; Karin, M. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature 1989, 337, 661-663. (Pubitemid 19054296)
113. Lotta, L. A.; Stetler-Stevenson, W. G. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. 1991, 51, 5054s-5059s.
114. Naylor, M. S.; Stamp, G. W.; Foulkes, W. D., Eccles, D.; Balkwill, F. R. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J. Clin. Invest. 1993, 91, 2194-2206. (Pubitemid 23141496)
115. Kulbe, H.; Thompson, R.; Wilson, J. L.; Robinson, S.; Hagemann, T.; Fatah, R., Gould, D.; Ayhan, A.; Balkwill, F. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007, 67, 585-592. (Pubitemid 46192196)
116. Bamias, A.; Koutsoukou, V.; Termos, E.; Tsiatas, M. L.; Liakos, C.; Tsitsilonis, O.; Rodolakis, A.; Voulgaris, Z.; Vlahos, G.; Papageorgiou, T.; Papatheodoridis, G.; Archimandritis, A.; Antsaklis, A.; Dimopoulos, M. A. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving firstline, platinum-based chemotherapy. Gynecol. Oncol. 2008, 108, 421-427.
117. Kusuda, T,; Shigemasa, K.; Arihiro, K.; Fujii, T.; Nagai, N.; Ohama, K. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol. Rep. 2005, 13, 1153-1158.
118. Marth, C.; Fiegl, H.; Zeimet, A. G.; Müller-Holzner, E.; Deibl, M.; Doppler, W.; Daxenbichler, G. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am. J. Obstet. Gynecol. 2004, 191, 1598-1605. (Pubitemid 39491185)
119. Hartenbach, E. M.; Olson, T. A.; Goswitz, J. J.; Mohanraj, D.; Twiggs, L. B.; Carson, L. F.; Ramakrishnan, S. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett. 1997, 121, 169-175. (Pubitemid 28008916)
120. Hazelton, D. A.; Hamilton, T. C. Vascular endothelial growth factor in ovarian cancer. Curr. Oncol. Rep. 1999, 1, 59-63.
121. Kraft, A.; Weindel, K.; Ochs, A.; Marth, C.; Zmija, J.; Schumacher, P.; Unger, C.; Marmé, D.; Gastl, G. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999, 85, 178-187. (Pubitemid 29031373)
122. Paley, P. J.; Staskus, K. A.; Gebhard, K.; Mohanraj, D.; Twiggs, L. B.; Carson, L. F.; Ramakrishnan, S. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997, 80, 98-106. (Pubitemid 27270925)
123. Tempfer, C.; Obermair, A.; Hefler, L.; Haeusler, G.; Gitsch, G.; Kainz, C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet. Gynecol. 1998, 92, 360-363. (Pubitemid 28396857)
124. Ferrara, N. Vascular endothelial growth factor. The trigger for neovascularization in the eye. Lab. Invest. 1995, 72, 615-618.
125. Terman, B. I.; Dougher-Vermazen, M.; Carrion, M. E.; Dimitrov, D.; Armellino, D. C.; Gospodarowicz, D.; Böhlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992, 187, 1579-1586.
126. Dikov, M. M.; Ohm, J. E.; Ray, N.; Tchekneva, E. E.; Burlison, J.; Moghanaki, D.; Nadaf, S.; Carbone, D. P. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 2005, 174, 215-222. (Pubitemid 40007407)
127. Lissoni, P.; Malugani, F.; Bonfanti, A.; Bucovec, R.; Secondino, S.; Brivio, F.; Ferrari-Bravo, A.; Ferrante, R.; Vigoré, L.; Rovelli, F.; Mandalà, M.; Viviani, S.; Fumagalli, L.; Gardani, G. S. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J. Biol. Regul. Homeost. Agents 2001, 15, 140-144. (Pubitemid 32717550)
128. Ohm, J. E.; Gabrilovich, D. I.; Sempowski, G. D.; Kisseleva, E.; Parman, K. S.; Nadaf, S.; Carbone, D. P. VEGF inhibits T-cell development and may
129. Shen, G. H.; Ghazizadeh, M.; Kawanami, O.; Shimizu, H.; Jin, E.; Araki, T.; Sugisaki, Y. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br. J. Cancer 2000, 83, 196-203. (Pubitemid 30411717)
130. Berek, J. S.; Chung, C.; Kaldi, K.; Watson, J. M.; Knox, R. M.; Martínez-Maza, O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am. J. Obstet. Gynecol. 1991, 164, 1038-1042.
131. Scambia, G.; Testa, U.; Panici, P. B.; Martucci, R.; Foti, E.; Petrini, M.; Amoroso, M.; Masciullo, V.; Peschle, C.; Mancuso, S. Interleukin-6 serum levels in patients with gynecological tumors. Int. J. Cancer 1994, 57, 318-323. (Pubitemid 24168603)
132. Tempfer, C.; Zeisler, H.; Sliutz, G.; Haeusler, G.; Hanzal, E.; Kainz, C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol. Oncol. 1997, 66, 27-30. (Pubitemid 27329303)
133. Gastl, G.; Plante, M.; Finstad, C. L.; Wong, G. Y.; Federici, M. G.; Bander, N. H.; Rubin, S. C. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br. J. Haematol. 1993, 83, 433-441. (Pubitemid 23080014)
134. Scambia, G.; Testa, U.; Benedetti Panici, P.; Foti, E.; Martucci, R.; Gadducci, A.; Perillo, A.; Facchini, V.; Peschle, C.; Mancuso, S. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br. J. Cancer 1995, 71, 354-356.
135. Fiorentino, D. F.; Zlotnik, A.; Vieira, P.; Mosmann, T. R.; Howard, M.; Moore, K. W.; O'Garra, A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 1991, 146, 3444-3451.
136. Yue, F. Y.; Dummer, R.; Geertsen, R.; Hofbauer, G.; Laine, E.; Manolio, S.; Burg, G. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int. J. Cancer 1997, 71, 630-637. (Pubitemid 27239375)
137. Merogi, A. J.; Marrogi, A. J.; Ramesh, R.; Robinson, W. R.; Fermin, C. D.; Freeman, S. M. Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum. Pathol. 1997, 28, 321-331. (Pubitemid 27106085)
138. Pisa, P.; Halapi, E.; Pisa, E. K.; Gerdin, E.; Hising, C.; Bucht, A.; Gerdin, B.; Kiessling, R. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc. Natl. Acad. Sci. USA 1992, 89, 7708-7712.
139. Berger, S.; Siegert, A.; Denkert, C.; Köbel, M.; Hauptmann, S. Interleukin-10 in serous ovarian carcinoma cell lines. Cancer Immunol. Immunother. 2001, 50, 328-333. (Pubitemid 32757465)
140. Nash, M. A.; Lenzi, R.; Platsoucas, C. D.; Freedman, R. S. RTPCR quantitation of cytokine responses in vivo from specimens containing small numbers of cells during bioimmunotherapy. J. Immunol. Methods 1998, 219, 169-179. (Pubitemid 28513162)
141. Zhou, J.; Ye, F.; Chen, H.; Lv, W.; Gan, N. The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J. Int. Med. Res. 2007, 35, 290-300. (Pubitemid 46971349)
142. Marth, C.; Zeimet, A. G.; Herold, M.; Brumm, C.; Windbichler, G.; Müller-Holzner, E.; Offner, F.; Feichtinger, H.; Zwierzina, H.; Daxenbichler, G. Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Int. J. Cancer 1996, 67, 826-830. (Pubitemid 26348812)
143. Chen, Z.; Fadiel, A.; Feng, Y.; Ohtani, K.; Rutherford, T.; Naftolin, F. Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor. Cancer 2001, 92, 3068-3075. (Pubitemid 33136203)
144. Mustea, A.; Pirvulescu, C.; Könsgen, D.; Braicu, E. I.; Yuan, S.; Sun, P.; Lichtenegger, W.; Sehouli, J. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine 2008, 42, 77-84.
145. Mellor, A. L.; Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004, 4, 762-774. (Pubitemid 39336293)
146. Munn, D. H.; Shafizadeh, E.; Attwood, J. T.; Bondarev, I.; Pascine, A.; Mellor, A. L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 1999, 189, 1363-1372. (Pubitemid 29227522)
147. Okamoto, A.; Nikaido, T.; Ochiai, K.; Takakura, S.; Saito, M.; Aoki, Y.; Ishii, N.; Yanaihara, N.; Yamada, K.; Takikawa, O.; Kawaguchi, R.; Isonishi, S.; Tanaka, T.; Urashima, M. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 2005, 11, 6030-6039. (Pubitemid 41170335)
148. Vitale, M.; Pelusi, G.; Taroni, B.; Gobbi, G.; Micheloni, C.; Rezzani, R.; Donato, F.; Wang, X.; Ferrone, S. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin. Cancer Res. 2005, 11, 67-72. (Pubitemid 40075779)
149. Rolland, P.; Deen, S.; Scott, I.; Durrant, L.; Spendlove, I. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin. Cancer Res. 2007, 13, 3591-3596. (Pubitemid 46955120)
150. Gamzatova, Z.; Villabona, L.; Dahlgren, L.; Dalianis, T.; Nillson, B.; Bergfeldt, K.; Masucci, G. V. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol. Oncol. 2006, 103, 145-150. (Pubitemid 44399802)
151. World Health Organization. Comprehensive cervical cancer control. A guide to essential practice. Genova: WHO 2006.
152. Walboomers, J. M.; Jacobs, M. V.; Manos, M. M.; Bosch, F. X.; Kummer, J. A.; Shah, K. V.; Snijders, P. J.; Peto, J.; Meijer, C. J.; Muñoz, N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189, 12-19. (Pubitemid 29406813)
153. Quinn, M. A.; Benedet, J. L.; Odicino, F.; Maisonneuve, P.; Beller, U.; Creasman, W. T.; Heintz, A. P.; Ngan, H. Y.; Pecorelli, S. Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 2006, 95(Suppl 1), S43-103.
154. Landoni, F.; Maneo, A.; Colombo, A.; Placa, F.; Dilani, R.; Perego, P.; Favoni, G.; Ferri, L.; Mangioni, C. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997, 350, 535-540. (Pubitemid 27348428)
155. Green, J. A.; Kirwan, J. M.; Tierney, J. F.; Symonds, P.; Fresco, L.; Collingwood, M.; Williams, C. J. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001, 358, 781-786. (Pubitemid 32868726)
156. Benedetti-Panici, P.; Greggi, S.; Colombo, A.; Amoroso, M.; Smaniotto, D.; Giannarelli, D.; Alunni, G.; Raspaglieli, F.; Zola, P.; Mangioni, C.; Landoni, F. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J. Clin. Oncol. 2002, 20, 179-188. (Pubitemid 34032610)
157. Zhou, J.; Sun, X. Y.; Stenzel, D. J.; Frazer, I. H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991, 185, 251-257.
158. Bryan, J. T. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 2007, 25, 3001-3006. (Pubitemid 46482731)
159. Cutts, F. T.; Franceschi, S.; Goldie, S.; Castellsague, X.; de Sanjose, S.; Garnett, G.; Edmunds, W. J.; Claeys, P.; Goldenthal, K. L.; Harper, D. M.; Markowitz, L. Human papillomavirus and HPV vaccines: a review. Bull. World Health Organ. 2007, 85, 719-726. (Pubitemid 47416724)
160. Bartolozzi, G.; Bona, G.; Ciofi, M.; De Martino, M.; Di Pietro, P.; Duse, M.; Esposito, S.; Gasparini, R.; Mariani, L.; Marostica, G.; Paravati, F.; Plebani, A.; Principi, N.; Zuccotti, G. V.; Tovo, P. A. Human papillomavirus vaccination. Consensus Conference in pediatric age. Minerva Pediatr. 2007, 59, 165-182. (Pubitemid 47066413)
161. Harper, D. M.; Franco, E. L.; Wheeler, C. M.; Moscicki, A. B.; Romanowski, B.; Roteli-Martins, C. M.; Jenkins, D.; Schuind, A.; Costa Clemens, S. A.; Dubin, G. HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367, 1247-1255.
162. Villa, L. L.; Costa, R. L.; Petta, C. A.; Andrade, R. P.; Ault, K. A.; Giuliano, A. R.; Wheeler, C. M.; Koutsky, L. A.; Malm, C.; Lehtinen, M.; Skjeldestad, F. E.; Olsson, S. E.; Steinwall, M.; Brown, D. R.; Kurman, R. J.; Ronnett, B. M.; Stoler, M. H.; Ferenczy, A.; Harper, D. M.; Tamms, G. M.; Yu, J.; Lupinacci, L.; Railkar, R.; Taddeo, F. J.; Jansen, K. U.; Esser, M. T.; Sings, H. L.; Saah, A. J.; Barr, E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet. Oncol. 2005, 6, 271-278. (Pubitemid 40590263)
163. Muñoz, N.; Bosch, F. X.; de Sanjosé, S.; Herrero, R.; Castellsagué, X.; Shah, K. V.; Snijders, P. J.; Meijer, C. J. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348, 518-527.
164. Daling, J. R.; Madeleine, M. M.; Schwartz, S. M.; Shera, K. A.; Carter, J. J.; McKnight, B.; Porter, P. L.; Galloway, D. A.; McDougall, J. K.; Temimi, H. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol. Oncol. 2002, 84, 263-270. (Pubitemid 34136778)
165. Bosch, F. X.; Lorincz, A.; Muñoz, N.; Meijer, C. J.; Shah, K. V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 2002, 55, 244-265. (Pubitemid 34293391)
166. Yang, L.; Li, R.; Mohr, I. J.; Clark, R.; Botchan, M. R. Activation of BPV-1 replication in vitro by the transcription factor E2. Nature 1991, 353, 628-632. (Pubitemid 21912571)
167. Choo, K. B.; Pan, C. C.; Han, S. H. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 1987, 161, 259-261. (Pubitemid 17161559)
168. Choo, K. B.; Lee, H. H.; Pan, C. C.; Wu, S. M.; Liew, L. N.; Cheung, W. F.; Han, S. H. Sequence duplication and internal deletion in the integrated human papilloma virus type 16 genome cloned from a cervical carcinoma. J. Virol. 1988, 62, 1659-1666. (Pubitemid 18133186)
169. Stanley, M. A. Replication of human papillomaviruses in cell culture. Antiviral Res. 1994, 24, 1-15. (Pubitemid 24171521)
170. Dyson, N.; Howley, P. M.; Münger, K.; Harlow, E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243, 934-937. (Pubitemid 19066153)
171. Scheffner, M.; Werness, B. A.; Huibregtse, J. M.; Levine, A. J.; Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990, 63, 1129-1136. (Pubitemid 120035062)
172. Moscicki, A. B.; Schiffman, M.; Kjaer, S.; Villa, L. L. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006, 24(Suppl 3), S42-S51. (Pubitemid 44308674)
173. Richardson, H.; Kelsall, G.; Tellier, P.; Voyer, H.; Abrahamowicz, M.; Ferenczy, A.; Coutlée, F.; Franco, E. L. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol. Biomarkers Prev. 2003, 12, 485-490. (Pubitemid 36713640)
174. Ho, G.Y.; Bierman, R.; Beardsley, L.; Chang, C. J.; Burk, R. D. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 1998, 338, 423-428. (Pubitemid 28135669)
175. Choo, K. B.; Pan, C. C.; Liu, M. S.; Ng, H. T.; Chen, C. P.; Lee, Y. N.; Chao, C. F.; Meng, C. L.; Yeh, M. Y.; Han, S. H. Presence of episomal and integrated human papillomavirus DNA sequences in cervical carcinoma. J. Med. Virol. 1987, 21, 101-107. (Pubitemid 17001948)
176. Lehn, H.; Villa, L. L.; Marpiona, F.; Hilgarth, M.; Hillemans, H. G.; Sauer, G. Physical state and biological activity of human papillomavirus genomes in precancerous lesions of the female genital tract. J. Gen. Virol. 1988, 69, 187-196. (Pubitemid 18064154)
177. Ho, G. Y.; Burk, R. D.; Fleming, I.; Klein, R. S. Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. Int. J. Cancer 1994, 56, 788-792. (Pubitemid 24102741)
178. Petry, K. U.; Scheffel, D.; Bode, U.; Gabrysiak, T.; Köchel, H.; Kupsch, E.; Glaubitz, M.; Niesert, S.; Kühnle, H.; Schedel, I. Cellular immunodeficiency enhances the progression of human papillomavirus- associated cervical lesions. Int. J. Cancer 1994, 57, 836-840. (Pubitemid 24216820)
179. Coleman, N.; Birley, H. D.; Renton, A. M.; Hanna, N. F.; Ryait, B. K.; Byrne, M.; Taylor-Robinson, D.; Stanley, M. A. Immunological events in regressing genital warts. Am. J. Clin. Pathol. 1994, 102, 768-774.
180. Villa, L. L.; Ault, K. A.; Giuliano, A. R.; Costa, R. L.; Petta, C. A.; Andrade, R. P.; Brown, D. R.; Ferenczy, A.; Harper, D. M.; Koutsky, L. A.; Kurman, R. J.; Lehtinen, M.; Malm, C.; Olsson, S. E.; Ronnett, B. M.; Skjeldestad, F. E.; Steinwall, M.; Stoler, M. H.; Wheeler, C. M.; Taddeo, F. J.; Yu, J.; Lupinacci, L.; Railkar, R.; Marchese, R.; Esser, M. T.; Bryan, J.; Jansen, K. U.; Sings, H. L.; Tamms, G. M.; Saah, A. J.; Barr, E. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006, 24, 5571-5583. (Pubitemid 44172918)
181. Frazer, I. H.; Thomas, R.; Zhou, J.; Leggatt, G. R.; Dunn, L.; McMillan, N.; Tindle, R. W.; Filgueira, L.; Manders, P.; Barnard, P.; Sharkey, M. Potential strategies utilised by papillomavirus to evade host immunity. Immunol. Rev. 1999, 168, 131-142. (Pubitemid 29276678)
182. Soto, U.; Das, B. C.; Lengert, M.; Finzer, P.; zur Hausen, H.; Rösl, F. Conversion of HPV 18 positive non-tumorigenic HeLafibroblast hybrids to invasive growth involves loss of TNF-alpha mediated repression of viral transcription and modification of the AP-1 transcription complex. Oncogene 1999, 18, 3187-3198. (Pubitemid 29286963)
183. Barnard, P.; McMillan, N. A. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999, 259, 305-313. (Pubitemid 29393381)
184. Barnard, P.; Payne, E.; McMillan, N. A. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha. Virology 2000, 277, 411-419.
185. Sheu, B. C.; Chiou, S. H.; Chang, W. C.; Chow, S. N.; Lin, H. H.; Chen, R. J.; Huang, S. C.; Ho, H. N.; Hsu, S. M. Integration of high-risk human papillomavirus DNA correlates with HLA genotype aberration and reduced HLA class I molecule expression in human cervical carcinoma. Clin. Immunol. 2005, 115, 295-301. (Pubitemid 40712325)
186. Dimitrakakis, C.; Kymionis, G.; Diakomanolis, E.; Papaspyrou, I.; Rodolakis, A.; Arzimanoglou, I.; Leandros, E.; Michalas, S. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol. Oncol. 2000, 77, 129-136. (Pubitemid 30217316)
187. Huang, L. W.; Chou, Y. Y.; Chao, S. L.; Chen, T. J.; Lee, T. T. p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecol. Oncol. 2001, 83, 348-354. (Pubitemid 33033078)
188. Avall-Lundqvist, E. H.; Silfverswärd, C.; Aspenblad, U.; Nilsson, B. R.; Auer, G. U. The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma. Eur. J. Cancer 1997, 33, 1799-1804. (Pubitemid 28129207)
189. Graflund, M.; Sorbe, B.; Karlsson, M. Immunohistochemical expression of p53, bcl-2, and p21 (WAF1/CIP1) in early cervical carcinoma: correlation with clinical outcome. Int. J. Gynecol. Cancer 2002, 12, 290-298. (Pubitemid 34787557)
190. Hunt, C. R.; Hale, R. J.; Buckley, C. H.; Hunt, J. p53 expression in carcinoma of the cervix. J. Clin. Pathol. 1996, 49, 971-974. (Pubitemid 27273806)
191. Ikuta, A.; Saito, J.; Mizokami, T.; Nakamoto, T.; Yasuhara, M.; Nagata, F.; Nakajima, M.; Matsuo, I.; Yasuda, K.; Kanzaki, H. Correlation p53 expression and human papilloma virus deoxyribonucleic acid with clinical outcome in early uterine cervical carcinoma. Cancer Detect. Prev. 2005, 29, 528-536. (Pubitemid 41758492)
192. Suzuki, Y.; Nakano, T.; Kato, S.; Ohno, T.; Tsujii, H.; Oka, K. Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: P53 status has a strong impact on prognosis. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60, 231-236. (Pubitemid 39165490)
193. Uchiyama, M.; Iwasaka, T.; Matsuo, N.; Hachisuga, T.; Mori, M.; Sugimori, H. Correlation between human papillomavirus positivity and p53 gene overexpression in adenocarcinoma of the uterine cervix. Gynecol. Oncol. 1997, 65, 23-29. (Pubitemid 27171547)
194. Wootipoom, V.; Lekhyananda, N.; Phungrassami, T.; Boonyaphiphat, P.; Thongsuksai, P. Prognostic significance of Bax, Bcl- 2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecol. Oncol. 2004, 94, 636-642. (Pubitemid 39194454)
195. Fujita, M.; Inoue, M.; Tanizawa, O.; Iwamoto, S.; Enomoto, T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res. 1992, 52, 5323-5328.
196. Helland, A.; Holm, R.; Kristensen, G.; Kaern, J.; Karlsen, F.; Trope, C.; Nesland, J. M.; Børresen, A. L. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J. Pathol. 1993, 171, 105-114. (Pubitemid 23309731)
197. Ngan, H. Y.; Tsao, S. W.; Liu, S. S.; Stanley, M. Abnormal expression and mutation of p53 in cervical cancer--a study at protein, RNA and DNA levels. Genitourin. Med. 1997, 73, 54-58. (Pubitemid 27076089)
198. Crook, T.; Wrede, D.; Tidy, J. A.; Mason, W. P.; Evans, D. J.; Vousden, K. H. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet 1992, 339, 1070-1073.
199. Park, S. Y.; Kang, Y. S.; Kim, B. G.; Lee, S. H.; Lee, E. D.; Lee, K. H.; Park, K. B.; Lee, J. H. Loss of heterozygosity on the short arm of chromosome 17 in uterine cervical carcinomas. Cancer Genet. Cytogenet. 1995, 79, 74-78.
200. Helland, A.; Karlsen, F.; Due, E. U.; Holm, R.; Kristensen, G.; Børresen-Dale, A. Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load. Br. J. Cancer 1998, 78, 69-72. (Pubitemid 28276772)
201. Ishikawa, H.; Mitsuhashi, N.; Sakurai, H.; Maebayashi, K.; Niibe, H. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone. Cancer 2001, 91, 80-89. (Pubitemid 32052617)
202. Milde-Langosch, K.; Albrecht, K.; Joram, S.; Schlechte, H.; Giessing, M.; Löning, T. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int. J. Cancer 1995, 63, 639-645.
203. Crawford, R. A.; Caldwell, C.; Iles, R. K.; Lowe, D.; Shepherd, J. H.; Chard, T. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br. J. Cancer 1998, 78, 210-214. (Pubitemid 28302258)
204. Baalbergen, A.; Ewing-Graham, P. C.; Eijkemans, M. J.; Helmerhorst, T. J. Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality. Int. J. Cancer 2007, 121, 106-110. (Pubitemid 46753857)
205. Tsuda, H.; Jiko, K.; Tsugane, S.; Yajima, M.; Yamada, T.; Tanemura, K.; Tsunematsu, R.; Ohmi, K.; Sonoda, T.; Hirohashi, S. Prognostic value of p53 protein accumulation in cancer cell nuclei in adenocarcinoma of the uterine cervix. Jpn. J. Cancer Res. 1995, 86, 1049-1053. (Pubitemid 3020050)
206. Waggoner, S. E.; Anderson, S. M.; Luce, M. C.; Takahashi, H.; Boyd, J. p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix. Gynecol. Oncol. 1996, 60, 339-344. (Pubitemid 26077615)
207. Hale, R. J.; Buckley, C. H.; Fox, H.; Williams, J. Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J. Clin. Pathol. 1992, 45, 594-596.
208. Kihana, T.; Tsuda, H.; Teshima, S.; Nomoto, K.; Tsugane, S.; Sonoda, T.; Matsuura, S.; Hirohashi, S. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994, 73, 148-153. (Pubitemid 24012735)
209. Nevin, J.; Laing, D.; Kaye, P.; McCulloch, T.; Barnard, R.; Silcocks, P.; Blackett, T.; Paterson, M.; Sharp, F.; Cruse, P. The significance of Erb-b2 immunostaining in cervical cancer. Gynecol. Oncol. 1999, 73, 354-358. (Pubitemid 29272854)
210. Roland, P. Y.; Stoler, M. H.; Broker, T. R.; Chow, L. T. The differential expression of the HER-2/neu oncogene among high-risk human papillomavirus- infected glandular lesions of the uterine cervix. Am. J. Obstet. Gynecol. 1997, 177, 133-138. (Pubitemid 27327324)
211. Baker, A. C.; Eltoum, I.; Curry, R. O.; Stockard, C. R.; Manne, U.; Grizzle, W. E.; Chhieng, D. Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. Arch. Pathol. Lab. Med. 2006, 130, 1510-1515. (Pubitemid 44520718)
212. Agarwal, S.; Sharma, S. Localization of carcinoembryonic antigen in uterine cervical neoplasia. Indian J. Med. Res. 1990, 92, 452-455.
213. Nanbu, Y.; Fujii, S.; Konishi, I.; Nonogaki, H.; Mori, T. Immunohistochemical localizations of CA 125, carcinoembryonic antigen, and CA 19-9 in normal and neoplastic glandular cells of the uterine cervix. Cancer 1988, 62, 2580-2588. (Pubitemid 19006443)
214. Lindgren, J.; Wahlström, T.; Seppälä, M. Tissue CEA in premalignant epithelial lesions and epidermoid carcinoma of the uterine cervix: prognostic significance. Int. J. Cancer 1979, 23, 448-453. (Pubitemid 9170891)
215. McDicken, I. W.; Rainey, M. The immunohistological demonstration of carcinoembryonic antigen in intra-epithelial and invasive squamous carcinoma of the cervix. Histopathology 1983, 7, 475-485.
216. Tendler, A.; Kaufman, H. L.; Kadish, A. S. Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinoma. Hum. Pathol. 2000, 31, 1357-1362. (Pubitemid 30949135)
217. Toki, T.; Yajima, A. Immunohistochemical localization of carcinoembryonic antigen (CEA) in squamous cell carcinoma of the uterine cervix: prognostic significance of localization pattern of CEA. Tohoku J. Exp. Med. 1991, 165, 25-32.
218. Lehtovirta, P.; Viinikka, L.; Ylikorkala, O. Comparison between squamous cell carcinoma-associated antigen and CA-125 in patients with carcinoma of the cervix. Gynecol. Oncol. 1990, 37, 276-278.
219. Takeda, M.; Sakuragi, N.; Okamoto, K.; Todo, Y.; Minobe, S.; Nomura, E.; Negishi, H.; Oikawa, M.; Yamamoto, R.; Fujimoto, S. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet. Gynecol. Scand. 2002, 81, 451-457. (Pubitemid 34527152)
220. Bender, D. P.; Sorosky, J. I.; Buller, R. E.; Sood, A. K. Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma. Am. J. Obstet. Gynecol. 2003, 189, 113-117. (Pubitemid 36886533)
221. Tsai, C. C.; Liu, Y. S.; Huang, E. Y.; Huang, S. C.; Chang, H. W.; Tseng, C. W.; ChangChien, C. C. Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis. Gynecol. Oncol. 2006, 100, 591-595. (Pubitemid 43246876)
222. Avall-Lundqvist, E. H.; Sjövall, K.; Nilsson, B. R.; Eneroth, P. H. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma. Eur. J. Cancer 1992, 28, 1695-1702.
223. Ngan, H. Y.; Cheung, A. N.; Lauder, I. J.; Cheng, D. K.; Wong, L. C.; Ma, H. K. Tumour markers and their prognostic value in adenocarcinoma of the cervix. Tumour Biol. 1998, 19, 439-444. (Pubitemid 28539325)
224. Scambia, G.; Benedetti Panici, P.; Foti, E.; Ferrandina, G.; Leone, F. P.; Marciano, M.; Mancuso, S. Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome. Eur. J. Cancer 1996, 32, 259-263. (Pubitemid 26092086)
225. Napoletano, C.; Bellati, F.; Tarquini, E.; Tomao, F.; Taurino, F.; Spagnoli, G.; Rughetti, A.; Muzii, L.; Nuti, M.; Benedetti Panici, P. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am. J. Obstet. Gynecol. 2008, 198, 99.e1-7 (Pubitemid 350309245)
226. Suminami, Y.; Kishi, F.; Sekiguchi, K.; Kato, H. Squamous cell carcinoma antigen is a new member of the serine protease inhibitors. Biochem. Biophys. Res. Commun. 1991, 181, 51-58.
227. Duk, J. M.; Groenier, K. H.; de Bruijn, H. W.; Hollema, H.; ten Hoor, K. A.; van der Zee, A. G.; Aalders, J. G. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J. Clin. Oncol. 1996, 14(1), 111-118.
228. Massuger, L. F.; Koper, N. P.; Thomas, C. M.; Dom, K. E.; Schijf, C. P. Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations. Gynecol. Oncol. 1997, 64, 473-476. (Pubitemid 27120439)
229. Scambia, G.; Panici P. B.; Baiocchi, G.; Amoroso, M.; Foti, E.; Greggi, S.; Mancuso, S. The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy. Am. J. Obstet. Gynecol. 1991, 164, 631-636.
230. Bolger, B. S.; Dabbas, M.; Lopes, A.; Monaghan, J. M. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol. Oncol. 1997, 65, 309-313. (Pubitemid 27216946)
231. Strauss, H. G.; Laban, C.; Lautenschläger, C.; Buchmann, J.; Schneider, I.; Koelbl, H. SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix. Eur. J. Cancer 2002, 38, 1987-1991.
232. Gadducci, A.; Tana, R.; Cosio, S.; Genazzani, A. R. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit. Rev. Oncol. Hematol. 2008, 66, 10-20. (Pubitemid 351324130)
233. Monnier-Benoit, S.; Mauny, F.; Riethmuller, D.; Guerrini, J. S.; Cpîlna, M.; Félix, S.; Seillès, E.; Mougin, C.; Prétet, J. L. Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. Gynecol. Oncol. 2006, 102, 22-31. (Pubitemid 44183744)
234. Nakamura, T.; Shima, T.; Saeki, A.; Hidaka, T.; Nakashima, A.; Takikawa, O.; Saito, S. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterinecervical cancer. Cancer Sci. 2007, 98, 874-881. (Pubitemid 46691826)
235. Nedergaard, B. S.; Nielsen, K.; Nyengaard, J. R.; Ladekarl, M. Stereologic estimation of the total numbers, the composition and the anatomic distribution of lymphocytes in cone biopsies from patients with stage I squamous cell carcinoma of the cervix uteri. APMIS 2007, 115, 1321-1330.
236. Piersma, S. J.; Jordanova, E. S.; van Poelgeest, M. I.; Kwappenberg, K. M.; van der Hulst, J. M.; Drijfhout, J. W.; Melief, C. J.; Kenter, G. G.; Fleuren, G. J.; Offringa, R.; van der Burg, S. H. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007, 67, 354-361. (Pubitemid 46142795)
237. Carter, J. J.; Koutsky, L. A.; Wipf, G. C.; Christensen, N. D.; Lee, S. K.; Kuypers, J.; Kiviat, N.; Galloway, D. A. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J. Infect. Dis. 1996, 174, 927-936. (Pubitemid 26357453)
238. Carter, J. J.; Koutsky, L. A.; Hughes, J. P.; Lee, S. K.; Kuypers, J.; Kiviat, N.; Galloway, D. A. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. 2000, 181, 1911-1919. (Pubitemid 30416152)
239. Hines, J. F.; Ghim, S. J.; Christensen, N. D.; Kreider, J. W.; Barnes, W. A.; Schlegel, R.; Jenson, A. B. Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination. Gynecol. Oncol. 1994, 55, 13-20. (Pubitemid 24336110)
240. Bontkes, H. J.; de Gruijl, T. D.; Bijl, A.; Verheijen, R. H.; Meijer, C. J.; Scheper, R. J.; Stern, P. L.; Burns, J. E.; Maitland, N. J.; Walboomers, J. M. Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia. J. Gen. Virol. 1999, 80, 2453-2459. (Pubitemid 29408375)
241. Nindl, I.; Zumbach, K.; Pawlita, M.; Teller, K.; Schneider, A.; Dürst, M. Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations. J. Infect. Dis. 2000, 181, 1764-1767. (Pubitemid 30387773)
242. Baay, M. F.; Duk, J. M.; Groenier, K. H.; Burger, M. P.; de Bruijn, H. W.; Hollema, H.; Stolz, E.; Herbrink, P. Relation between HPV-16 serology and clinico-pathological data in cervical carcinoma patients: prognostic value of anti-E6 and/or anti-E7 antibodies. Cancer Immunol. Immunother. 1997, 44, 211-215. (Pubitemid 27288129)
243. Silins, I.; Avall-Lundqvist, E.; Tadesse, A.; Jansen, K. U.; Stendahl, U.; Lenner, P.; Zumbach, K.; Pawlita, M.; Dillner, J.; Frankendal, B. Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol. Oncol. 2002, 85, 333-338. (Pubitemid 34522995)
244. Clerici, M.; Shearer, G. M.; Clerici, E. Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J. Natl. Cancer Inst. 1998, 90, 261-263.
245. Romagnani, S. Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int. Arch. Allergy Immunol. 1992, 98, 279-285.
246. Gey, A.; Fumari, P.; Sambandam, A.; Lecuru, F.; Cassare, L.; Badoual, C.; Fridman, C.; Nagarajan, B.; Fridman, W. H.; Tartour, E. Identification and characterisation of a group of cervical carcinoma patients with profound downregulation of intratumoral Type 1 (IFNgamma) and Type 2 (IL-4) cytokine mRNA expression. Eur. J. Cancer 2003, 39, 595-603. (Pubitemid 36287371)
247. de Gruijl, T. D.; Bontkes, H. J.; van den Muysenberg, A. J.; van Oostveen, J. W.; Stukart, M. J.; Verheijen, R. H.; van der Vange, N.; Snijders, P. J.; Meijer, C. J.; Walboomers, J. M.; Scheper, R. J. Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur. J. Cancer 1999, 35, 490-497. (Pubitemid 29157871)
248. Grohmann, U.; Orabona, C.; Fallarono, F.; Vacca, C.; Calcinaro, F.; Falorni, A.; Candeloro, P.; Belladonna, M. L.; Bianchi, R.; Fioretti, M. C.; Puccetti, P. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 2002, 3, 1097-1101. (Pubitemid 35363664)
249. Mellor, A. L.; Baban, B.; Chandler, P.; Marshall, B.; Jhaver, K.; Hansen, A.; Koni, P. A.; Iwashima, M.; Munn, D. H. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 2003, 171, 1652-1655. (Pubitemid 36966447)
250. Miwa, N.; Hayakawa, S.; Miyazaki, S.; Myojo, S.; Sasaki, Y.; Sakai, M.; Takikawa, O.; Saito, S. IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous abortion. Mol. Hum. Reprod. 2005, 11, 865-870.
251. Sorosky, J. I. Endometrial cancer. Obstet. Gynecol. 2008, 111, 436-447. (Pubitemid 351653438)
252. Huh, W. K.; Straughn, J. M. Jr.; Mariani, A.; Podratz, K. C.; Havrilesky, L. J.; Alvarez-Secord, A.; Gold, M. A.; McMeekin, D. S.; Modesitt, S.; Cooper, A. L.; Powell, M. A.; Mutch, D. G.; Nag, S.; Alvarez, R. D.; Cohn, D. E. Salvage
253. McCluggage, W. G.; Connolly, L. E.; McGregor, G.; Hyland, P. L.; Hall, P. A. A Strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia. Int. J. Gynecol. Pathol. 2005, 24, 307-312. (Pubitemid 41368280)
254. Alkushi, A.; Lim, P.; Coldman, A.; Huntsman, D.; Miller, D.; Gilks, C. B. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int. J. Gynecol. Pathol. 2004, 23, 129-137. (Pubitemid 38391772)
255. Graesslin, O.; Chantot-Bastaraud, S.; Lorenzato, M.; Birembaut, P.; Quéreux, C.; Daraï, E. Fluorescence in situ hybridization and immunohistochemical analysis of p53 expression in endometrial cancer: prognostic value and relation to ploidy. Ann. Surg. Oncol. 2008, 15, 484-492.
256. Kounelis, S.; Kapranos, N.; Kouri, E.; Coppola, D.; Papadaki, H.; Jones, M. W. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod. Pathol. 2000, 13, 379-388.
257. Zheng, W.; Cao, P.; Zheng, M.; Kramer, E. E.; Godwin, T. A. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol. Oncol. 1996, 61, 167-174. (Pubitemid 26145719)
258. Enomoto, T.; Fujita, M.; Inoue, M.; Rice, J. M.; Nakajima, R.; Tanizawa, O.; Nomura, T. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res. 1993, 53, 1883-1888. (Pubitemid 23127119)
259. Jiko, K.; Sasano, H.; Ito, K.; Ozawa, N.; Sato, S.; Yajima, A. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus. Anticancer Res. 1993, 13, 305-310. (Pubitemid 23196761)
260. Ito, K.; Watanabe, K.; Nasim, S.; Sasano, H.; Sato, S.; Yajima, A.; Silverberg, S. G.; Garrett, C. T. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res. 1994, 54, 4667-4670. (Pubitemid 24276491)
261. Hetzel, D. J.; Wilson, T. O.; Keeney, G. L.; Roche P. C.; Cha, S. S.; Podratz, K. C. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol. Oncol. 1992, 47, 179-185. (Pubitemid 23001325)
262. Lambropoulou, M.; Stefanou, D.; Alexiadis, G.; Tamiolakis, D.; Tripsianis, G.; Chatzaki, E.; Vandoros, G. P.; Kiziridou, A.; Papadopoulou, E.; Papadopoulos, N. Cytoplasmic expression of c-erb-B2 in endometrial carcinomas. Onkologie 2007, 30, 495-500. (Pubitemid 47462059)
263. Berchuck, A.; Rodriguez, G.; Kinney, R. B.; Soper, J. T.; Dodge, R. K.; Clarke-Pearson, D. L.; Bast, R. C. Jr. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am. J. Obstet. Gynecol. 1991, 164, 15-21.
264. Santin, A. D.; Bellone, S.; Gokden, M.; Palmieri, M.; Dunn, D.; Agha, J.; Roman, J. J.; Hutchins, L.; Pecorelli, S.; O'Brien, T.; Cannon, M. J.; Parham, G. P. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin. Cancer Res. 2002, 8, 1271-1279. (Pubitemid 34517668)
265. Aplin, J. D.; Hey, N. A.; Graham, R. A. Human endometrial MUC1 carries keratan sulfate: characteristic glycoforms in the luminal epithelium at receptivity. Glycobiology 1998, 8, 269-276. (Pubitemid 28137661)
266. Hey, N. A.; Li, T. C.; Devine, P. L.; Graham, R. A.; Saravelos, H.; Aplin, J. D. MUC1 in secretory phase endometrium: expression in precisely dated biopsies and flushings from normal and recurrent miscarriage patients. Hum. Reprod. 1995, 10, 2655-2662.
267. Hey, N. A.; Aplin, J. D. Sialyl-Lewis x and Sialyl-Lewis a are associated with MUC1 in human endometrium. Glyconjug. J. 1996, 13, 769-779. (Pubitemid 26354270)
268. Sivridis, E.; Giatromanolaki, A.; Koukourakis, M. I.; Georgiou, L.; Anastasiadis, P. Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance. Histopathology 2002, 40, 92-100. (Pubitemid 34107387)
269. Hewetson, A.; Chilton, B. S. Molecular cloning and hormone-dependent expression of rabbit Muc1 in the cervix and uterus. Biol. Reprod. 1997, 57, 468-477. (Pubitemid 27343710)
270. Hoffman, L. H.; Olson, G. E.; Carson, D. D.; Chilton, B. S. Progesterone and implanting blastocysts regulate Muc1 expression in rabbit uterine epithelium. Endocrinology 1998, 139, 266-271. (Pubitemid 28166319)
271. Morrison, C.; Merati, K.; Marsh, W. L. Jr.; De Lott, L.; Cohn, D. E.; Young, G.; Frankel, W. L. The mucin expression profile of endometrial carcinoma and correlation with clinical-pathologic parameters. Appl. Immunohistochem. Mol. Morphol. 2007, 15, 426-431. (Pubitemid 350307849)
272. Mylonas, I.; Mayr, D.; Walzel, H.; Shabani, N.; Dian, D.; Kuhn, C.; Kunze, S.; Jeschke, U.; Friese, K. Mucin 1, Thomsen- Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis. Anticancer Res. 2007, 27, 1975-1980. (Pubitemid 46954711)
273. Alkushi, A.; Irving, J.; Hsu, F.; Dupuis, B.; Liu, C. L.; Rijn, M.; Gilks, C. B. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch. 2003, 442, 271-277. (Pubitemid 36399222)
274. Dabbs, D. J.; Sturtz, K.; Zaino, R. J. The immunohistochemical discrimination of endometrioid adenocarcinomas. Hum. Pathol. 1996, 27, 172-177. (Pubitemid 26049471)
275. Dallenbach-Hellweg, G.; Lang-Avérous, G.; Hahn, U. The value of immunohistochemistry in the differential diagnosis of endometrial carcinomas. APMIS Suppl. 1991, 23, 91-99.
276. Reid-Nicholson, M.; Iyengar, P.; Hummer, A. J.; Linkov, I.; Asher, M.; Soslow, R. A. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod. Pathol. 2006, 19, 1091-1100. (Pubitemid 44106724)
277. de Bruijn, H. W.; van Beeck Calkoen-Carpay, T.; Jager, S.; Duk, J. M.; Aalders, J. G.; Fleuren, G. J. The tumor marker CA 125 is a common constituent of normal cervical mucus. Am. J. Obstet. Gynecol. 1986, 154, 1088-1091. (Pubitemid 16085735)
278. Podczaski, E.; Kaminski, P. F.; Zaino, R. CA 125 and CA 19-9 immunolocalization in normal, hyperplastic, and carcinomatous endometrium. Cancer 1993, 71, 2551-2556. (Pubitemid 23100490)
279. Ginath, S.; Menczer, J.; Fintsi, Y.; Ben-Shem, E.; Glezerman, M.; Avinoach, I. Tissue and serum CA125 expression in endometrial cancer. Int. J. Gynecol. Cancer 2002, 12, 372-375. (Pubitemid 34839835)
280. Yamazawa, K.; Hirashiki, K.; Usui, H.; Mitsuhashi, A.; Matsui, H.; Sekiya, S. Discordance between serum level and tissue immunohistochemical staining of CA125 in endometrioid adenocarcinoma of the uterine corpus. Int. J. Gynecol. Pathol. 2005, 24, 254-259. (Pubitemid 40885079)
281. Nur, S.; Chuang, L.; Ramaswamy, G. Immunohistochemical characterization of cancer antigen in uterine cancers. Int. J. Gynecol. Cancer 2006, 16, 1903-1910. (Pubitemid 44470054)
282. Chung, H. H.; Kim, J. W.; Park, N. H.; Song, Y. S.; Kang, S. B.; Lee, H. P. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet. Gynecol. Scand. 2006, 85, 1501-1505. (Pubitemid 44863771)
283. Kukura, V.; Zovko, G.; Ciglar, S.; Markulin-Grgi, L.; Santek, F.; Podgajski, M.; Dui, Z. Serum CA-125 tumor marker in endometrial adenocarcinoma. Eur. J. Gynaecol. Oncol. 2003, 24, 151-153. (Pubitemid 36389358)
284. Takac, I.; Gorisek, B. Serum CA 125 levels and lymph node metastasis in patients with endometrial cancer. Wien Klin Wochenschr. 2006, 118(Suppl 2), 62-65. (Pubitemid 43989537)
285. Abramovich, D.; Markman, M.; Kennedy, A.; Webster, K.; Belinson, J. Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma. J. Cancer Res. Clin. Oncol. 1999, 125, 697-698.
286. Chitale, D.A.; Jungbluth, A. A.; Marshall, D. S.; Leitao, M. M.; Hedvat, C. V.; Kolb, D.; Spagnoli, G. C.; Iversen, K.; Soslow, R. A. Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. Mod. Pathol. 2005, 18, 119-126. (Pubitemid 40128104)
287. Resnick, M. B.; Sabo, E.; Kondratev, S.; Kerner, H.; Spagnoli, G. C.; Yakirevich, E. Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas. Int. J. Cancer 2002, 101, 190-195. (Pubitemid 34970912)
288. Kondratiev, S.; Sabo, E.; Yakirevich, E.; Lavie, O.; Resnick, M. B. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin. Cancer Res. 2004, 10, 4450-4456. (Pubitemid 38878888)
289. Ino, K.; Yamamoto, E.; Shibata, K.; Kajiyama, H.; Yoshida, N.; Terauchi, M.; Nawa, A.; Nagasaka, T.; Takikawa, O.; Kikkawa, F. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin. Cancer Res. 2008, 14, 2310-2317. (Pubitemid 351551062)
290. Miyatake, T.; Tringler, B.; Liu, W.; Liu, S. H.; Papkoff, J.; Enomoto, T.; Torkko, K. C.; Dehn, D. L.; Swisher, A.; Shroyer, K. R. B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor Tcell infiltration. Gynecol. Oncol. 2007, 106, 119-127. (Pubitemid 46898579)
291. Ambros, R. A.; Kurman, R. J. Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. Cancer 1992, 69, 1424-1431.
292. Lee, K. R.; Vacek, P. M.; Belinson, J. L. Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid adenocarcinoma. Gynecol. Oncol. 1994, 54, 10-18. (Pubitemid 24239401)
293. Yamazawa, K.; Seki, K.; Matsui, H.; Sekiya, S. Significance of perivascular lymphocytic infiltrates in endometrial carcinoma. Cancer 2001, 91, 1777-1784. (Pubitemid 32377964)
294. Hashimoto, I.; Kodama, J.; Seki, N.; Hongo, A.; Miyagi, Y.; Yoshinouchi, M.; Kudo, T. Macrophage infiltration and angiogenesis in endometrial cancer. Anticancer Res. 2000, 20, 4853-4856. (Pubitemid 32127741)
295. Tanaka, Y.; Kobayashi, H.; Suzuki, M.; Kanayama, N.; Suzuki, M.; Terao, T. Thymidine phosphorylase expression in tumor-infiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer. Hum. Pathol. 2002, 33, 1105-1113. (Pubitemid 35416708)
296. Soeda, S.; Nakamura, N.; Ozeki, T.; Nishiyama, H.; Hojo, H.; Yamada, H.; Abe, M.; Sato, A. Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol. Oncol. 2008, 109, 122-128.
297. Ohno, S.; Ohno, Y.; Suzuki, N.; Kamei, T.; Koike, K.; Inagawa, H.; Kohchi, C.; Soma, G.; Inoue, M. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 2004, 24, 3335-3342. (Pubitemid 39390949)
298. Coppola, D.; Fu, L.; Nicosia, S. V.; Kounelis, S.; Jones, M. Prognostic significance of p53, bcl-2, vimentin, and S100 proteinpositive Langerhans cells in endometrial carcinoma. Hum. Pathol. 1998, 29, 455-462. (Pubitemid 28213464)
299. Honig, A.; Schaller, N.; Dietl, J.; Backe, J.; Kammerer, U. S100 as an immunohistochemically-detected marker with prognostic significance in endometrial carcinoma. Anticancer Res. 2005, 25, 1747-1753. (Pubitemid 40896797)
300. Yamazawa, K.; Shimada, H.; Hirai, M.; Hirashiki, K.; Ochiai, T.; Ishikura, H.; Shozu, M.; Isaka, K. Serum p53 antibody as a diagnostic marker of high-risk endometrial cancer. Am. J. Obstet. Gynecol. 2007, 197, 505.e1-7 (Pubitemid 350007388)
301. Singer, C. F.; Marbaix, E.; Kokorine, I.; Lemoine, P.; Donnez, J.; Eeckhout, Y.; Courtoy, P. J. Paracrine stimulation of interstitial collagenase (MMP-1) in the human endometrium by interleukin 1alpha and its dual block by ovarian steroids. Proc. Natl. Acad. Sci. USA 1997, 94, 10341-10345. (Pubitemid 27407043)
302. Singer, C. F.; Kronsteiner, N.; Marton, E.; Walter, I.; Kubista, M.; Czerwenka, K.; Schreiber, M.; Tschugguel, W.; Wieser, F.; Kubista, E. Interleukin-1 system and sex steroid receptor gene expression in human endometrial cancer. Gynecol. Oncol. 2002, 85, 423-430. (Pubitemid 34651879)
303. Fujimoto, J.; Sakaguchi, H.; Aoki, I.; Tamaya, T. Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res. 2000, 15, 2632-2635. (Pubitemid 30318237)
304. Koch, A. E.; Polverini, P. J.; Kunkel, S. L.; Harlow, L. A.; DiPietro, L. A.; Elner, V. M.; Elner, S. G.; Strieter, R. M. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258, 1798-1801. (Pubitemid 23087348)
305. Zhang, L.; Scott, P. A.; Turley, H.; Leek, R.; Lewis, C. E.; Gatter, K. C.; Harris, A. L.; Mackenzie, I. Z.; Rees, M. C.; Bicknell, R. Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium. J. Pathol. 1998, 185, 402-408. (Pubitemid 28355973)
306. Chen, C. A.; Cheng, W. F.; Lee, C. N.; Wei, L. H.; Chu, J. S.; Hsieh, F. J.; Hsieh, C. Y. Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival. Gynecol. Oncol. 2001, 80, 207-212. (Pubitemid 32158460)
307. Guidi, A. J.; Abu-Jawdeh, G.; Tognazzi, K.; Dvorak, H. F.; Brown, L. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 1996, 78, 454-460. (Pubitemid 26250531)
308. Kamat, A. A.; Merritt, W. M.; Coffey, D.; Lin, Y. G.; Patel, P. R.; Broaddus, R.; Nugent, E.; Han, L. Y.; Landen, C. N. Jr.; Spannuth, W. A.; Lu, C.; Coleman, R. L.; Gershenson, D. M.; Sood, A. K. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin. Cancer Res. 2007, 13, 7487-7495.
309. Salvesen, H. B.; Akslen, L. A. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int. J. Cancer 1999, 84, 538-543.
310. Gold, L. I.; Saxena, B.; Mittal, K. R.; Marmor, M.; Goswami, S.; Nactigal, L.; Korc, M.; Demopoulos, R. I. Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res. 1994, 54, 2347-2358. (Pubitemid 24980022)
311. Gold, L. I.; Parekh, T. V. Loss of growth regulation by transforming growth factor-beta (TGF-beta) in human cancers: studies on endometrial carcinoma. Semin. Reprod. Endocrinol. 1999, 17, 73-92. (Pubitemid 29293555)
312. Van Themsche, C.; Mathieu, I.; Parent, S.; Asselin, E. Transforming growth factor-beta3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent up-regulation of X-linked inhibitor of apoptosis and protein kinase c-dependent induction of matrix metalloproteinase-9. J. Biol. Chem. 2007, 282, 4794-4802. (Pubitemid 47100989)
313. Parekh, T. V.; Gama, P.; Wen, X.; Demopoulos, R.; Munger, J. S.; Carcangiu, M. L.; Reiss, M.; Gold, L. I. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition. Cancer Res. 2002, 62, 2778-2790. (Pubitemid 34525761)
314. Piestrzeniewicz-Ulanska, D.; Brys, M.; Semczuk, A.; Jakowicki, J. A.; Krajewska, W. M. Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium. Cancer Lett. 2002, 186, 231-239. (Pubitemid 35246208)
315. Chopra, V.; Dinh, T. V.; Hannigan, E. V. Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J. Cancer Res. Clin. Oncol. 1997, 123, 167-172. (Pubitemid 27153355)
316. Ino, K.; Yoshida, N.; Kajiyama, H.; Shibata, K.; Yamamoto, E.; Kidokoro, K.; Takahashi, N.; Terauchi, M.; Nawa, A.; Nomura, S.; Nagasaka, T.; Takikawa, O.; Kikkawa, F. Indoleamine 2,3- dioxygenase is a novel prognostic indicator for endometrial cancer. Br. J. Cancer 2006, 95, 1555-1561. (Pubitemid 44863359)
317. Barrier, B. F.; Kendall, B. S.; Sharpe-Timms, K. L.; Kost, E. R. Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol. Oncol. 2006, 103, 25-30. (Pubitemid 44389864)
318. Beller, U.; Quinn, M. A.; Benedet, J. L.; Creasman, W. T.; Ngan, H. Y.; Maisonneuve, P.; Pecorelli, S.; Odicino, F.; Heintz, A. P. Carcinoma of the vulva. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 2006, 95(Suppl 1), S7-S27.
319. Jones, R. W.; Baranyai, J.; Stables, S. Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet. Gynecol. 1997, 90, 448-452. (Pubitemid 27357940)
320. Homesley, H. D.; Bundy, B. N.; Sedlis, A.; Adcock, L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet. Gynecol. 1986, 68, 733-740. (Pubitemid 17190208)
321. Peh, W. C.; Khong, P. L.; Sham, J. S.; Ho, W. Y.; Yeung, H. W. Sacral and pubic insufficiency fractures after irradiation of gynaecological malignancies. Clin. Oncol. (R Coll Radiol). 1995, 7, 117-122.
322. Carlson, J. A.; Ambros, R.; Malfetano, J.; Ross, J.; Grabowski, R.; Lamb, P.; Figge, H.; Mihm, M. C. Jr. Vulvar lichen sclerosus and squamous cell carcinoma: a cohort, case control, and investigational study with historical perspective; implications for chronic inflammation and sclerosis in the development of neoplasia. Hum. Pathol. 1998, 29, 932-948. (Pubitemid 28422041)
323. Kagie, M. J.; Kenter, G. G.; Zomerdijk-Nooijen, Y.; Hermans, J.; Schuuring, E.; Timmers, P. J.; Trimbos, J. B.; Fleuren, G. J. Human papillomavirus infection in squamous cell carcinoma of the vulva, in various synchronous epithelial changes and in normal vulvar skin. Gynecol. Oncol. 1997, 67, 178-183. (Pubitemid 27500416)
324. Kagie, M. J.; Kenter, G. G.; Tollenaar, R. A.; Hermans, J.; Trimbos, J. P.; Fleuren, G. J. p53 protein overexpression, a frequent observation in squamous cell carcinoma of the vulva and in various synchronous vulvar epithelia, has no value as a prognostic parameter. Int. J. Gynecol. Pathol. 1997, 16, 124-130. (Pubitemid 27231292)
325. Brustmann, H.; Naudé, S. Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions. Gynecol. Oncol. 2002, 86, 192-199. (Pubitemid 34953504)
326. Kohlberger, P.; Kainz, C.; Breitenecker, G.; Gitsch, G.; Sliutz, G.; Kölbl, H.; Tschachler, E.; Reinthaller, A. Prognostic value of immunohistochemically detected p53 expression in vulvar carcinoma. Cancer 1995, 76, 1786-1789.
327. Berchuck, A.; Rodriguez, G.; Kamel, A.; Soper, J. T.; Clarke-Pearson, D. L.; Bast, R. C. Jr. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet. Gynecol. 1990, 76, 381-387. (Pubitemid 20264521)
328. Gordinier, M. E.; Steinhoff, M. M.; Hogan, J. W.; Peipert, J. F.; Gajewski, W. H.; Falkenberry, S. S.; Granai, C. O. S-Phase fraction, p53, and HER-2/neu status as predictors of nodal metastasis in early vulvar cancer. Gynecol. Oncol. 1997, 67, 200-202. (Pubitemid 27500420)
329. Fanning, J.; Lambert, H. C.; Hale, T. M.; Morris, P. C.; Schuerch, C. Paget's disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget's disease, and recurrence after surgical excision. Am. J. Obstet. Gynecol. 1999, 180, 24-27. (Pubitemid 29088383)
330. Kuan, S. F.; Montag, A. G.; Hart, J.; Krausz, T.; Recant, W. Differential expression of mucin genes in mammary and extramammary Paget's disease. Am. J. Surg. Pathol. 2001, 25, 1469-1477. (Pubitemid 33096960)
331. Horn, L. C.; Purz, S.; Krumpe, C.; Bilek, K. COX-2 and Her-2/neu are overexpressed in Paget's disease of the vulva and the breast: results of a preliminary study. Arch. Gynecol. Obstet. 2008, 277, 135-138. (Pubitemid 350308029)
332. Brummer, O.; Stegner, H. E.; Böhmer, G.; Kühnle, H.; Petry, K. U. HER-2/neu expression in Paget disease of the vulva and the female breast. Gynecol. Oncol. 2004, 95, 336-340. (Pubitemid 39445869)
333. Bellati, F.; Napoletano, C.; Tarquini, E.; Palaia, I.; Landi, R.; Manci, N.; Spagnoli, G.; Rughetti, A.; Panici P. B.; Nuti, M. Cancer testis antigen expression in primary and recurrent vulvar cancer: association with prognostic factors. Eur. J. Cancer 2007, 43, 2621-2627. (Pubitemid 350086939)
334. Gul, N.; Ganesan, R.; Luesley, D. M. Characterizing T-cell response in low-grade and high-grade vulval intraepithelial neoplasia, study of CD3, CD4 and CD8 expressions. Gynecol. Oncol. 2004, 94, 48-53. (Pubitemid 38950497)
335. Bourgault Villada, I.; Moyal Barracco, M.; Ziol, M.; Chaboissier, A.; Barget, N.; Berville, S.; Paniel, B.; Jullian, E.; Clerici, T.; Maillère, B.; Guillet, J. G. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res. 2004, 64, 8761-8766. (Pubitemid 39552094)
336. Todd, R. W.; Roberts, S.; Mann, C. H.; Luesley, D. M.; Gallimore, P. H.; Steele, J. C. Human papillomavirus (HPV) type 16-specific CD8+ T cell responses in women with high grade vulvar intraepithelial neoplasia. Int. J. Cancer 2004, 108, 857-862. (Pubitemid 38112614)
337. Yamawaki, T.; Takeshima, N.; Shimizu, Y.; Teshima, H.; Hasumi, K. Serum levels of squamous cell carcinoma antigen and carcinoembryonic antigen as tumor markers of vulvar cancer. J. Obstet. Gynaecol. Res. 1996, 22, 341-346. (Pubitemid 26288330)
338. Grimm, C.; Six, L.; Tomovski, C.; Speiser, P.; Joura, E.; Zeillinger, R.; Sliutz, G.; Reinthaller, A.; Hefler, L. A. A common interleukin-6 promoter polymorphism in patients with vulvar cancer. J. Soc. Gynecol. Investig. 2005, 12, 617-620. (Pubitemid 41737728)
339. Bancher-Todesca, D.; Obermair, A.; Bilgi, S.; Kohlberger, P.; Kainz, C.; Breitenecker, G.; Leodolter, S.; Gitsch, G. Angiogenesis in vulvar intraepithelial neoplasia. Gynecol. Oncol. 1997, 64, 496-500. (Pubitemid 27120445)
340. Doldi, N.; Origoni, M.; Bassan, M.; Ferrari, D.; Rossi, M.; Ferrari, A. Vascular endothelial growth factor. Expression in human vulvar neoplastic and nonneoplastic tissues. J. Reprod. Med. 1996, 41, 844-848. (Pubitemid 26404921)
341. Hefler, L.; Tempfer, C.; Obermair, A.; Frischmuth, K.; Sliutz, G.; Reinthaller, A.; Leodolter, S.; Kainz, C. Serum concentrations of vascular endothelial growth factor in vulvar cancer. Clin. Cancer Res. 1999, 5, 2806-2809. (Pubitemid 29493955)
342. Lewy-Trenda, I.; Wierzchniewska-awska, A.; Papierz, W. Expression of vascular endothelial growth factor (VEGF) in vulvar squamous cancer and VIN. Pol. J. Pathol. 2005, 56, 5-8. (Pubitemid 40732865)
343. Obermair, A.; Kohlberger, P.; Bancher-Todesca, D.; Tempfer, C.; Sliutz, G.; Leodolter, S.; Reinthaller, A.; Kainz, C.; Breitenecker, G.; Gitsch, G. Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancer. Gynecol. Oncol. 1996, 63, 204-209. (Pubitemid 26398600)
344. Zitvogel, L.; Apetoh, L.; Ghiringhelli, F.; Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008, 8, 59-73.
345. Horstmann, E.; McCabe, M. S.; Grochow, L.; Yamamoto, S.; Rubinstein, L.; Budd, T.; Shoemaker, D.; Emanuel, E. J.; Grady, C. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N. Engl. J. Med. 2005, 352, 895-904.
346. Hudis, C. A. Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 2007, 357, 39-51. (Pubitemid 47026733)
347. Peoples, G. E.; Gurney, J. M.; Hueman, M. T.; Woll, M. M.; Ryan, G. B.; Storrer, C. E.; Fisher, C.; Shriver, C. D.; Ioannides, C. G.; Ponniah, S. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J. Clin. Oncol. 2005, 23, 7536-7545. (Pubitemid 46291817)